Single versus combinatorial therapies in status epilepticus: Novel data from preclinical models

Area of Science:

• Neuroscience
• Pharmacology
• Epileptology

Background:

• Drug-refractory status epilepticus (RSE) is a life-threatening neurological emergency with high mortality and severe long-term effects.
• Current treatment strategies for RSE are often insufficient, and the underlying mechanisms of drug resistance remain unclear.
• Animal models, such as the pilocarpine and lithium-pilocarpine rat models, are crucial for understanding RSE and developing effective therapies.

Purpose of the Study:

• To investigate rational polytherapies for terminating status epilepticus (SE) and preventing its long-term neurological sequelae.
• To test the hypothesis that cholinergic mechanisms contribute to antiseizure drug (ASD) resistance in SE.
• To evaluate a novel intravenous polytherapy comprising diazepam, phenobarbital, and scopolamine for RSE treatment.

Main Methods:

• Utilized pilocarpine and lithium-pilocarpine rat models to induce status epilepticus (SE).
• Administered a novel intravenous polytherapy (diazepam, phenobarbital, scopolamine) at different time points after SE onset.
• Assessed the efficacy of the polytherapy in terminating SE and preventing long-term outcomes, including epilepsy and hippocampal damage, comparing it with monotherapies and other polytherapies.

Main Results:

• The scopolamine-containing polytherapy irreversibly terminated SE when administered 60, 90, or 120 minutes after SE onset.
• This novel polytherapy demonstrated comparable efficacy to ketamine-based polytherapies in terminating SE.
• Importantly, administration at 60 minutes post-SE onset prevented the development of epilepsy and hippocampal neurodegeneration, effects not seen with diazepam or diazepam/phenobarbital combinations.

Conclusions:

• Rational polytherapy is more effective than monotherapy for treating SE and may offer a clinically useful strategy for RSE.
• The developed scopolamine-containing cocktail represents a promising therapeutic approach for RSE, addressing both acute seizure termination and long-term neuroprotection.
• Further preclinical evidence supports combinatorial therapy as a viable option for managing RSE and mitigating its devastating consequences.